Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.57), $0.24 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.9 million versus the consensus estimate of $65.88 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Oregon Pacific Bancorp (ORPB) Tops Q2 EPS by 38c
• ArcelorMittal Q2 2026 analyst consensus: $2.04B EBITDA expected